Fermentation of TCM is a process that integrates traditional TCM processing theory with modern microbial fermentation technology. It involves the biological transformation of Chinese medicinal raw materials by utilizing specific microorganisms or their metabolites under controlled environmental conditions, such as temperature, pH, and humidity (Li et al., 2020). It originates from ancient traditional fermentation practices, which were historically applied to the fermentation of meats, wines, and dairy products (Cavalieri et al., 2003; Leroy et al., 2023; Zheng et al., 2022). During the Eastern Han Dynasty, Zhang Zhongjing described fermented Chinese medicinal substances such as Massa Medicata Fermentata in his Synopsis of the Golden Chamber. By this period, fermentation techniques in TCM had begun to take shape. Among the formulas recorded in the Treatise on Cold Damage, the application of the Zhizichi Decoction stands as a landmark example of fermentation technology finding its initial application within the realm of formulaic medicine. With the advancement of modern biotechnology, TCM fermentation technology has made significant progress with the help of modern technologies such as microbial technology, fermentation engineering, and bioengineering. TCM fermentation is usually categorized into three types according to the fermentation method: solid-state fermentation, submerged fermentation, and bidirectional fermentation of medicinal fungi in TCM (Zhang X. et al., 2023).

TCM fermentation is the process of transforming, decomposing, synthesizing, or modifying the active, inactive, or toxic components in TCM raw materials by utilizing the metabolic activities of microorganisms. Most macromolecular compounds in TCM are difficult for the body to digest, absorb and utilize without microbial fermentation. Many of the active ingredients of TCM need to be biotransformed by microorganisms in order to be biologically active (Lee et al., 2012). This also indirectly indicates that fermentation technology plays an essential role in the process of the therapeutic effectiveness of TCM. During the metabolic decomposition of substrates, microorganisms not only release primary metabolites such as ethanol and carbon dioxide, which are necessary for their growth, but also synthesize a variety of non-growth-essential compounds, which are called secondary metabolites, after the stabilization period. Their variety is extensive, covering a wide range of antibiotics, specific peptides (e.g., antimicrobial peptides), pigments, and growth factors (Méndez-Hernández et al., 2023; Robinson et al., 2001). Since these compounds have biological activities such as anti-infective, anti-inflammatory, and anticancer, they fall into the category of bioactive compounds. After fermentation treatment, TCM can improve the conversion efficiency of its intrinsic components and the rate of generation of novel compounds, making TCM fermentation technology a vital fresh approach to produce novel active compounds with strong medicinal value (Hussain et al., 2016). In addition to this, the fermentation process can effectively reduce the toxic effects of typical compounds such as lactones, toxic glycosides, and anthraquinones found in traditional Chinese medicines (Zhang X. et al., 2023). In general, TCM fermentation has the advantages of generating new substances, enhancing efficacy, and reducing toxicity. The fermentation process has the benefits of low energy consumption, simple equipment requirements, and the ability to retain more lipophilic components, thus embodying the principles of green pharmaceutical production. In recent years, the regulatory effects of fermented TCM on gut microbiota have increasingly come to public attention. This has opened up novel avenues for research in green pharmaceutical development, enabling fermentation techniques to align with TCM processing principles while simultaneously providing fresh perspectives for novel drug discovery (Figure 1).

Initially, research proposed that the human gut microbiota consisted of around 500–1,000 bacterial species. In contrast, a recent comprehensive study revealed that the number of bacterial species in the human gut is estimated to be between 15,000 and 36,000 (Frank et al., 2007). Healthy gut microbiota consists mainly of Firmicutes and Bacteroidetes, with Actinobacteria and Verrucomicrobia as the secondary phyla (Jandhyala, 2015). These bacteria work synergistically to strengthen the intestinal epithelial barrier by regulating the expression of tight junction proteins. They also produce metabolites such as SCFAs (e.g., butyrate) that nourish intestinal mucosal cells, thereby protecting intestinal integrity and promoting overall health (Morrison and Preston, 2016). The diversity and abundance of bacteria will vary significantly with the location of the digestive tract. Notably, over two-thirds of the body's microorganisms reside in the large intestine, which predominantly comprises Firmicutes and Bacteroidetes. Conversely, species such as Campylobacter spp., Salmonella spp., Vibrio cholerae spp., Escherichia coli, and Bacteroides fragilis are less prevalent (Gillespie et al., 2011; The Human Microbiome Project Consortium, 2012). Typically, the gut microbiota discussed in the context of disease states refers mostly to the colonic flora. In healthy individuals, the gut microbiota maintains a symbiotic and mutually beneficial relationship with its host. This symbiotic relationship confers essential metabolic regulation, immune homeostasis, and intestinal protection to the organism (Belkaid and Hand, 2014; Sonnenburg et al., 2005). The gut microbiota functions as an “organ” within the body, performing unique roles and exerting extensive metabolic regulatory effects on the host.

An increasing body of evidence indicates that the development of many chronic diseases is associated with dysbiosis of the gut microbiota (Chen Y. et al., 2021; Fan and Pedersen, 2021). The gut microbiota is a significant factor that influences the body's internal environment (Belkaid and Hand, 2014), and this association is particularly prominent in T2DM. In individuals with T2DM, the α-diversity (a measure of species richness and evenness) of the gut microbiota tends to be decreased compared to healthy individuals. Notably, an imbalance in the proportions of Firmicutes and Bacteroidetes is observed, characterized by an elevated Firmicutes/Bacteroidetes (F/B) ratio (Bahar-Tokman et al., 2022; Chen Z. et al., 2021). Compared with healthy individuals, both individuals with prediabetes and T2DM patients exhibit distinct differences in their gut microbiota (Zhong et al., 2019). To obtain further detailed information on the composition of the gut microbiota of patients with T2DM, Qin et al. (2012) developed a metagenome-wide association study (MGWAS) protocol. The analysis of this study revealed moderate intestinal dysbiosis in patients with T2DM, as evidenced by decreased abundance of some common butyric acid-producing bacteria and increased abundance of conditionally pathogenic bacteria. Simultaneously, microorganisms with sulfate-reducing capacity and resistance to oxidative stress were also enriched. In a study examining the gut microbiota of Indian patients with T2DM, researchers observed a characteristic pattern of microbial alterations: increased abundance of the Firmicutes, reduced abundance of the Bacteroidetes, alongside significant enrichment of the Verrucomicrobia and Proteobacteria (Beura et al., 2024). In a comprehensive review of 13 clinical trials, Wang et al. (2021) distinctly highlighted the role played by gut microbiota in the development and progression of T2DM.

The specific mechanisms whereby gut microbiota dysbiosis contributes to the development of T2DM encompass three main areas: the endotoxin theory, the short-chain fatty acid theory, and the bile acid theory (Ma et al., 2019) (Figure 2). From the endotoxin theory perspective, dysbiosis directly increases pro-inflammatory bacteria (e.g., Escherichia coli) while decreasing anti-inflammatory and beneficial bacteria (e.g., Bifidobacterium), leading to reduced microbial diversity. Opportunistic pathogens can trigger chronic low-grade inflammation by producing endotoxins (lipopolysaccharides), thereby disrupting glucose metabolism (Zhong et al., 2019; Di Vincenzo et al., 2024). Regarding the short-chain fatty acid theory, SCFAs (primarily acetate, propionate, and butyrate) are the main metabolites produced by gut microbiota fermenting dietary fiber. They serve not only as the primary energy source for intestinal epithelial cells but also effectively promote intestinal mucosal repair, enhance intestinal barrier defense functions, and play a positive preventive role in various intestinal inflammatory responses such as ulcerative colitis (Shin et al., 2023). Furthermore, substantial evidence indicates that SCFAs exert anti-obesity and anti-diabetic effects (Portincasa et al., 2022). Conversely, gut microbiota dysbiosis reduces SCFA-producing bacteria, leading to significantly diminished SCFA production. This ultimately destabilizes glucose homeostasis and induces T2DM onset (Portincasa et al., 2022; Sanna et al., 2019). In the bile acid hypothesis, bile acids function as “metabolic signaling molecules,” transmitting signals through nuclear receptors [e.g., Farnesoid X receptor (FXR)] and G protein-coupled receptors [e.g., Takeda G-protein-coupled receptor 5 (TGR5)] to regulate glucose-lipid metabolism (Singh et al., 2019). Notably, a bidirectional reciprocal relationship exists between gut microbiota and bile acids: on one hand, bile acids shape gut microbiota diversity and structural balance; on the other, gut microbiota directly determines the types and proportions of secondary bile acids (Guo et al., 2022). When gut microbiota imbalance occurs, it leads to insufficient secondary bile acid production, which in turn causes inadequate activation of TGR5/FXR. This ultimately results in insulin resistance and elevated blood glucose levels (Chen et al., 2023). More critically, insulin resistance further reduces gallbladder contractility, diminishing bile acid secretion and weakening its regulatory effect on the microbiota, thereby accelerating the progression of type 2 diabetes (Guo et al., 2022; Cadena Sandoval and Haeusler, 2025).

In recent times, a growing body of research has endeavored to enhance T2DM by regulating the gut microbiota through the supplementation of probiotics and prebiotics (Iatcu et al., 2021). Probiotics may be simply understood as a specific category of live microorganisms. When consumed in appropriate quantities, probiotics exert beneficial effects on the host's health. They can colonize directly within the gut, thereby participating in the regulation of the intestinal microecological balance. In this process, probiotics suppress the growth and reproduction of harmful bacteria by competing for nutrients and occupying living space (Wang et al., 2021). The results of several clinical studies have shown that patients with T2DM who have continuously consumed probiotics containing a variety of strains of bacteria are not only well-tolerated, but also have positive changes in a number of health indicators, such as blood glucose and blood lipids (Okesene-Gafa et al., 2020; Perraudeau et al., 2020; Zikou et al., 2023). Prebiotics (e.g., fructooligosaccharides, galactooligosaccharides, inulin, and lactulose) are non-digestible food components that selectively stimulate the growth and activity of particular beneficial bacteria (one or more species) within the gut, thereby exerting a beneficial effect on the host. Simply put, prebiotics can be analogized to “food” for beneficial bacteria (Li et al., 2021). Clinical studies have found that daily supplementation with prebiotics (i.e., inulin-type oligofructose) results in significant increases in fecal Bifidobacterium counts and SCFA levels in patients with T2DM. This confirms the potential of prebiotics for improving the intestinal microenvironment in patients with T2DM (Birkeland et al., 2020). It is evident that modulating the gut microbiota offers a novel strategy for improving T2DM. However, it should be noted that current research on probiotics and prebiotics still faces significant limitations, lacking unified clinical application standards. This inconsistency hinders the comparability and broader application of research findings (Suez et al., 2019; Roberfroid et al., 2010). Thus, regulating gut microbiota to improve T2DM is a new strategy. At this stage, the fermentation technology of TCM is gradually moving toward the research field, and both the pure TCM fermentation technology and the TCM combined with probiotic fermentation technology are highly respected. Compared with the traditional treatment, the advantages of TCM fermentation technology are significant. TCM fermentation technology is expected to become a novel technology for regulating the gut microbiota to assist in improving T2DM.

TCM fermentation technology, building upon conventional processing methods and integrating modern microbiological techniques, facilitates the decomposition and metabolism of medicinal substances. This process enhances therapeutic efficacy by expanding or generating novel active constituents. Numerous studies have shown that the bioactive components (e.g., polysaccharides and phenols) produced by TCM fermentation play a key role in regulating the gut microbiota structure, effectively increasing the abundance of beneficial bacteria in the intestinal tract, reducing the proportion of harmful bacteria, and restoring gut microbiota balance. As a special class of carbohydrates, polysaccharides derived from TCM cannot be directly digested or absorbed by the mammalian gut. In the lower part of the intestinal tract, they can play the role of “prebiotics” and become the nutrient source and substrate in the process of microbial fermentation, thus promoting the growth and activity of some beneficial bacterial communities (Wu et al., 2022). Astragalus membranaceus (Fisch.) Bunge, first documented in the Divine Farmer's Classic of Materia Medica, stands as a pivotal tonic herb in TCM for replenishing qi and ascending yang. It is not only frequently employed to alleviate typical qi deficiency symptoms such as fatigue and poor appetite with loose stools, but also serves as a crucial component in traditional formulations for treating “Xiaoke” (a classic TCM diagnosis characterized by polydipsia, polyphagia, polyuria and emaciation, primarily corresponding to DM in modern medicine) (Wang et al., 2023). Paecilomyces cicadae is a fungus with medicinal and edible properties. Zhou et al. (2022) employed SSF of Astragalus membranaceus (Fisch.) Bunge using Paecilomyces cicadae. Analysis of the SSF product revealed that flavonoids, saponins, and polysaccharides are its primary bioactive constituents. This fermentation product could effectively regulate the abundance of gut microbiota of mice with Diabetic Nephropathy (DN), including Ruminococcaceae_UCG-014, Allobaculum, Unclassified_f__Lachnospiraceae Alloprevotella, and Bacteroides. Concurrently, it improves the physiological condition of DN mice, demonstrating superior efficacy compared to Astragalus membranaceus (Fisch.) Bunge. Dendrobium (primarily utilizing the stem as the medicinal part) is a traditional Chinese medicinal herb renowned for its efficacy in nourishing the stomach, promoting fluid production, replenishing yin, and clearing heat. It has long been employed in the treatment of “Xiaoke.” Modern medical research has focused extensively on its rich phytochemical properties, with studies indicating its active constituents hold significant potential in both the treatment and prevention of diabetes (Li et al., 2023). Zou et al. (2025) employed fecal fluid from db/db mice to ferment Dendrobium officinale Kimura & Migo, Dendrobium huoshanense Z.Z. Tang & S.J. Cheng, Dendrobium nobile Lindl., and Dendrobium chrysotoxum Lindl., with fecal fluid from normal rats as a control. They monitored changes in the content of total polysaccharides and total polyphenols in the four Dendrobium species after fermentation. Results showed that the content of bioactive components (total polysaccharides and total polyphenols) increased in all four fermented Dendrobium species. These fermented species exhibited potent antioxidant and free radical scavenging activities, significantly regulated the diversity of gut microbiota by increasing the relative abundance of Bacteroidota, and promoted the production of SCFAs, thereby exerting a hypoglycaemic effect.

TCM fermentation technology can change how the gut bacteria work and impact the production of substances like SCFAs, which exert a significant impact on intestinal health and blood glucose regulation. Fermenting certain Chinese herbal medicines can boost the synthesis of SCFAs, such as acetic acid, propionic acid, and butyric acid. These metabolites play a role in adjusting intestinal pH values, participating in the regulation of energy metabolism, and delivering a beneficial effect on blood glucose management. Acetic acid primarily regulates systemic energy balance and appetite control. It enhances tissue responsiveness to insulin, promoting glucose uptake and utilization while improving insulin resistance. It also enters the central nervous system via the bloodstream, activating appetite regulation pathways to increase satiety and reduce overeating (Martin-Gallausiaux et al., 2021; González Hernández et al., 2019). Propionic acid targets glucose and lipid metabolism through hepatic metabolic pathways. Increased hepatic blood flow reduces triglyceride levels in the liver, thereby improving hepatic and systemic glucose homeostasis (Chambers et al., 2015). Butyric acid possesses potent anti-inflammatory effects, effectively strengthening tight junctions between intestinal epithelial cells. This reduces intestinal permeability, lowers systemic inflammatory responses, and alleviates insulin resistance (Wang et al., 2012). Astragalus polysaccharides (APS), as the primary constituents of the Chinese medicinal herb Astragalus membranaceus (Fisch.) Bunge, constitute the key active components for treating diabetes mellitus. Research has found that APS in vitro simulated fermentation effectively increased the abundance of beneficial bacteria in the fecal microbiota of T2DM patients, while simultaneously elevating propionic acid levels within SCFAs as measured by gas chromatography-mass spectrometry. This alteration induced GLP-1 and peptide YY (PYY) production, inhibited pancreatic β-cell apoptosis, and stimulated insulin secretion, thereby producing therapeutic improvements in T2DM (Zhang et al., 2024). Xiexin Decoction (XXD) is a traditional classical formula comprising three Chinese medicinal herbs: Scutellaria baicalensis Georgi, Coptis chinensis Franch., and Rheum palmatum L. It possesses the efficacy of clearing heat and detoxifying. Its therapeutic effect on T2DM has been validated through millennia of clinical practice, demonstrating reliable therapeutic efficacy. An experimental study investigating the effects of XXD on dyslipidemia in high-fat diet-induced obese rats revealed that this formula modulates gut microbiota composition. It promotes the fermentation of indigestible plant polysaccharides by saccharolytic bacteria in the colon, thereby increasing the production of SCFAs derived from the gut microbiome. SCFAs, by participating in energy metabolism regulation pathways, activate the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)/uncoupling protein-2 (UCP-2) signaling pathway. This reduces energy charge in obese rats, ultimately improving obesity-related insulin resistance (Xiao et al., 2019).

An increasing number of studies have revealed that the integrity of the intestinal mucosal barrier plays a crucial role in the onset of T2DM (Shen et al., 2019). Furthermore, TCM fermentation products can improve the integrity of the intestinal mucosal barrier and reduce intestinal permeability. They also play a key role in preventing endotoxins from entering the bloodstream and alleviating the body's inflammatory response. SCFAs, as the main metabolites of gut microbiota, have been shown to be an important energy source for intestinal epithelial cells. They can modulate the activity of intestinal epithelial cells through diverse mechanisms, controlling their growth, specialization, and the activity of subsets such as enteroendocrine cells, thereby influencing intestinal movement. This also serves as a critical factor in boosting the intestinal barrier function and overseeing the host's metabolism (Zhang D. et al., 2023). While maintaining the anaerobic environment of the colon and promoting the balance of microbiota, SCFAs, particularly butyric acid, can reduce intestinal permeability and promote epithelial barrier function through the hypoxia-inducible factor (HIF) (Kelly et al., 2015). In addition, butyric acid has been found to upregulate the expression of mucin-2 (MUC2) and the goblet cell marker gene (SPDEF) in experiments conducted both in live organisms and in laboratory settings, thereby thickening the mucus layer and strengthening the protective effect of the mucous membrane (Liang et al., 2022). More importantly, the mucus layer physically blocks direct contact between endotoxins and the intestinal epithelium, reducing endotoxin adhesion and cellular invasion, thereby lowering the incidence of “leaky gut” (Di Vincenzo et al., 2024). Metabolic substances like endotoxins cannot enter the portal venous circulation, sparing the liver from inflammatory responses triggered by continuous exposure to these substances and ultimately mitigating the disruption of hepatic glucose and lipid metabolism caused by inflammation. Furthermore, when a small fraction of butyrate signals reach the liver via the portal vein, they can activate the peroxisome proliferator-activated receptor (PPAR) pathway. This pathway modulates human adipose tissue regulatory T cells, suppressing the transcription and expression of key hepatic gluconeogenesis enzymes and thereby lowering fasting blood glucose levels (Chen B. et al., 2025). Song et al. (2024a) observed that Dendrobium officinale Kimura & Migo extract promotes SCFA formation during in vitro fermentation. In db/db mice, this extract further enhances SCFA production by improving gut microbiota diversity and bolsters intestinal integrity through increased expression of colonic tight junction proteins (ZO-1 and Occludin). Furthermore, this extract may activate the PPAR pathway via the gut-liver axis, thus collectively generating advantageous impacts on metabolic syndrome triggered by T2DM.

With the advancement of research on intestinal microecology and metabolic diseases, more and more evidence suggests that intestinal immune homeostasis imbalance is an important driver of T2DM development, and that the pathological process of T2DM can be significantly ameliorated by modulating intestinal immune function (Riedel et al., 2022). Current research has definitively verified that fermented TCM, especially when fermented with Lactobacillus, can substantially boost its immunoregulatory efficacy. This outcome is achieved through activating the body's inherent and acquired immune mechanisms while maintaining intestinal immune balance (Zhu et al., 2022). Ginseng trifolium (L.) Alph.Wood, as a widely recognized medicinal plant in traditional medicine, plays an important role in guarding against and addressing T2DM (Xie et al., 2005). Fan et al. (2021) found that fermentation-treated Ginseng trifolium (L.) Alph.Wood could effectively alleviate lipopolysaccharide (LPS)-induced inflammatory responses and significantly enhance the structural and functional integrity of the intestinal barrier in mice by modulating the TLR4/MAPK signaling pathway. This provides a “prerequisite for restoring the integrity of the intestinal mucosal barrier and regulating intestinal immune function.” Moreover, as investigations into the metabolic derivative SCFAs have advanced, it has been unveiled that SCFAs inhibit inflammatory reactions in human monocytes by inducing the secretion of prostaglandin E2 (PGE2) and enhancing the production of the anti-inflammatory cytokine interleukin-10 (IL-10), thus preserving intestinal immune functionality (Cox et al., 2009). Zhang et al. (2024) explored the effects of APS on gut microbiota and metabolites in T2DM patients using an in vitro simulated fermentation model. The results showed that APS fermentation increased the levels of all-trans retinoic acid and thiamine. Both have antioxidant properties and can be enriched in KEGG pathways such as thiamine metabolism, enhancing the antioxidant properties of feces. Correlation analysis has verified a notable positive correlation between Lactobacillus and thiamine and DPPH clearance, indicating that the antioxidant activity of APS is linked to its capacity to enhance specific bacteria and elevate their metabolites. Modern studies have also confirmed that antioxidant activity can be regarded as a “protective shield” for intestinal immune function (Bhattacharyya et al., 2014). The antioxidant activity of APS effectively protects the integrity of the intestinal barrier and balances the function of immune cells, providing a solid foundation for intestinal immune defense. Sijunzi Decoction (SJZD) is a classic formula in TCM renowned for its properties of tonifying qi and strengthening the spleen. Clinically, it is frequently used as the foundational prescription for patients with T2DM who present with a spleen-deficiency syndrome, with modifications made according to individual clinical manifestations. Polysaccharides are the primary active constituents of SJZD. Using an in vitro simulated fermentation model, researchers have demonstrated that the purified homogeneous polysaccharide component (S-3-1) from this decoction significantly modulates the abundance of gut bacterial genera while concurrently increasing the production of SCFAs, thereby exerting immunomodulatory effects through these mechanisms (Gao et al., 2018) (Figure 3).

In the development of new drugs and technologies, most researchers conduct extensive and systematic experimental research to ensure the safety of subjects and guarantee the scientific validity of findings. During the experimental phase of TCM fermentation preparations for T2DM, their hypoglycaemic activity, mechanisms of action, and safety are primarily validated through cellular models, animal models, and in vitro simulation experiments, providing a scientific basis for subsequent clinical studies. Current research predominantly uses classical hypoglycaemic Chinese herbs as fermentation substrates, which are combined with probiotics for biotransformation. Fermentation processes are optimized to improve active ingredient content and bioavailability. The classic formula of Danggui Buxue Decoction (DBD) is composed of the Astragalus membranaceus (Fisch.) Bunge and Angelica sinensis (Oliv.) Diels at a 5:1 ratio. DBD is primarily valued in TCM for its efficacy in replenishing qi and generating blood. Clinically, it is frequently used to address conditions such as sallow complexion and physical fatigue, which are typical manifestations of qi-blood deficiency syndrome. This formula exerts marked therapeutic effects on prolonged cases of DM and its associated complications in patients who present with qi-blood deficiency syndrome. Guo et al. (2020) conducted relevant research in which they fermented the herbal extract of DBD. They subsequently found that the fermented DBD exhibited enhanced activities in inhibiting α-glucosidase, scavenging DPPH free radicals, and inhibiting glycosylation, resulting in effectively enhancing its antidiabetic function. Gegen Qinlian Decoction (GQD) is primarily used in TCM for its efficacy in resolving exterior syndromes, clearing heat, drying dampness, and relieving diarrhea. This formula exerts its effects mainly by clearing heat and drying dampness, thereby alleviating symptoms such as excessive thirst with frequent drinking, loose stools, and diarrhea. Yan et al. (2018) found that the hypoglycaemic activity of fermented GQD was significantly higher than that of unfermented GQD, and concluded that the antidiabetic activity of Chinese herbal formulas can be improved by applying fermentation technology. Red Yeast Rice (RYR) is a medicinal substance produced by fermenting rice with Monascus purpureus. It possesses properties that promote blood circulation and disperse blood stasis, while also fortifying the spleen and aiding digestion. It may assist in alleviating symptoms of diabetes mellitus, including fatigue and limb numbness arising from prolonged illness. Modern research has revealed its significant anti-hyperglycemic activity (Zhu et al., 2019). In a study by Chang et al. (2006), researchers administered RYR via gastric gavage for 2 consecutive weeks to diabetic rat models induced by streptozotocin. Results demonstrated that RYR significantly reduced plasma glucose levels in diabetic rats. Further mechanistic analysis indicated that this hypoglycaemic effect was closely associated with RYR's ability to inhibit hepatic gluconeogenesis in diabetic rats.

Clinical investigations of fermented TCM preparations predominantly build upon safety and efficacy data obtained from experimental studies. Through methodologies such as randomized controlled trials (RCTs), their hypoglycaemic effects are validated in T2DM patients, aiming to explore novel approaches for clinically guarding against and addressing T2DM. Red ginseng [processed from Ginseng trifolium (L.) Alph.Wood], as a traditional Chinese medicinal herb, is renowned in TCM for its potent tonic properties, including greatly replenishing primordial qi (yuan qi), restoring the pulse to prevent collapse, and tonifying qi to control blood. It is frequently used to address conditions such as severe primordial qi depletion, cold limbs with a faint pulse, and fatigue arising from qi deficiency. For cases of diabetes mellitus characterized by pronounced qi deficiency, red ginseng may be incorporated to assist in the therapeutic regimen. A 4-week randomized, double-blind, placebo-controlled clinical trial conducted by the Functional Food Clinical Trial Center of Chonbuk National University Hospital of TCM found that adding fermented red ginseng (FRG) resulted in a notable decrease in postprandial blood glucose levels and raised postprandial insulin levels in comparison to the placebo group. Research findings confirmed that FRG possesses the capability to reduce postprandial blood glucose levels in subjects with impaired fasting glucose or T2DM (Oh et al., 2014). In TCM, Chaenomeles sinensis (Dum.Cours.) Koehne is characterized by the properties of soothing the sinews, dredging the meridians, regulating the stomach, and resolving dampness. Clinically, it is often combined with other TCM herbs to alleviate disorders of glucose and lipid metabolism in patients with T2DM. A randomized controlled clinical trial conducted at the SSRN Hospital Heart Center in Pamplemousses demonstrated that daily supplementation with 6 g of fermented Chaenomeles sinensis (Dum.Cours.) Koehne preparation over 14 weeks improved the overall health status of multiple organs affected by oxidative stress in patients with diabetes. These findings validate the potential application of fermented TCM in diabetes management and its associated complications (Somanah et al., 2012).

In the field of guarding against and addressing T2DM, with the persistent rise in global incidence rates and the limitations of traditional intervention methods, finding innovative pathways that combine long-term safety, clear efficacy, and multi-target regulatory characteristics has become one of the core focuses of medical research. TCM fermentation technology, rooted in ethnic medicine, has become a focal point of research because of its distinct mechanisms of action and considerable clinical effects. It is noteworthy that, based on the preceding introduction to fermentation technology, we can observe that different fermentation processes exert a significant influence on the hypoglycemic effects of TCM. This factor has also become a critical constraint on the standardized application and maximization of efficacy for fermented TCM. Current research progress indicates that an increasing number of researchers, through experimental studies and clinical validation, have confirmed the broad application prospects of TCM fermentation technology in improving T2DM. Collectively, research findings demonstrate that the value of TCM fermentation technology in T2DM combating has been recognized by most researchers, and its translational pathway from experimental research to clinical application is becoming more evident. Based on the aforementioned exploration of mechanisms whereby fermented Chinese herbal medicines modulate gut microbiota to improve T2DM, it is reasonable to infer that among the numerous mechanisms through which fermented Chinese herbal preparations ameliorate T2DM, regulating the structure and functionality of the gut microbiota constitutes a core and pivotal component. Its significance in disease intervention has been partially substantiated by current research (Table 1).